BLFS insider sale: CMO disposes 289 shares under 10b5-1 plan

Rhea-AI Filing Summary

BioLife Solutions (BLFS) reported an insider transaction by its Chief Marketing Officer. On October 9, 2025, the officer sold 289 shares of common stock at $27.36 per share. Following the sale, the officer beneficially owned 133,617 shares, held directly. The filing notes the sale was made under a Rule 10b5-1(c) trading plan effective January 3, 2023, established to satisfy tax withholding obligations related to the vesting of restricted stock.

Insights

Insider trading & compliance analyst

Small, pre‑planned insider sale under a 10b5‑1 plan.

The CMO sold 289 shares at $27.36 on October 9, 2025. The filing states this occurred pursuant to a Rule 10b5‑1(c) plan effective January 3, 2023, tied to tax withholding from restricted stock vesting.

After the transaction, the officer held 133,617 shares directly. This is an administrative, pre‑scheduled sale; actual market impact depends on broader trading activity and holder decisions.

Insider Trade Summary

Net Seller: 289 shares

Net Sell 1 txn

Insider Berard Todd

Role Chief Marketing Officer

Sold 289 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock	289	$27.36	$8K

Holdings After Transaction: Common Stock — 133,617 shares (Direct)

Footnotes (1)

1. F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

What insider transaction did BLFS report?

The Chief Marketing Officer sold 289 shares of common stock on October 9, 2025.

At what price were the BLFS shares sold?

The shares were sold at $27.36 per share.

How many BLFS shares does the officer hold after the sale?

Following the transaction, the officer beneficially owned 133,617 shares, held directly.

Was the BLFS insider sale under a 10b5-1 plan?

Yes. It was pursuant to a Rule 10b5-1(c) plan effective January 3, 2023.

What was the stated purpose of the sale by the BLFS officer?

To satisfy tax withholding obligations related to the vesting of restricted stock.

What is the role of the reporting person at BLFS?

The reporting person is an Officer, serving as Chief Marketing Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 10/14/2025 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Berard Todd

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		S(1)		289	D	$27.36	133,617	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Todd Berard	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.